Lorcaserine in combination with XR-Naltrexone for relapse prevention opioid use disorder
| Sponsor: |
NIDA |
| Enrolling: |
Male and Female Patients |
| Study Length: |
8 Weeks |
| Clinic Visits: |
20 |
| IRB Number: |
7501 |
| U.S. Govt. ID: |
NCT03169816 |
| Contact: |
Daniel Brooks: 212-923-3031 / daniel.brooks@nyspi.columbia.edu |
This study proposes to recruit patients with Opioid Use Disorder (OUD) seeking treatment into our program of a 5 day outpatient detoxification and naltrexone induction followed by a relapse-prevention treatment with Extended release-naltrexone (XR-NTX) for 8 weeks.
This study is closed
Investigator
Frances Levin, MD
| Have you been using opiates or heroin for at least 6 months? |
Yes |
No |
| Are you seeking to stop using opiates or heroin? |
Yes |
No |